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Corporate and Social Responsibility Report 2002Do more, feel better, live longer
Corporate responsibility is an integral
part of our business – it is inherent in the
mission of our company. GlaxoSmithKline
makes a significant positive contribution to
society around the world, through the
medicines and healthcare products that we
research, develop, manufacture and sell. 
Impact of Medicines cover story
Although a generation separates them, Bettina Bartels and her son Philippe
are able to lead active lives despite both suffering from asthma. Their story
can be found in our Annual Review. On page 5 of this report, Dr Vincent
McGovern gives his perspective on asthma management as both a patient
and a doctor.
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A global challenge
The responsible behaviour of all types 
of organisations, including multinational
companies, governments and charities, is high on
the public agenda and stimulates considerable
debate. Last year, in our first review of corporate
and social responsibility, which covered GSK’s
first year as a new company, we set out our
commitment to connecting business decisions 
to ethical, social and environmental concerns1.
In this report, which covers activity during 2002, 
we cover the issues that have generated significant
interest from stakeholders. We have made good
progress this year, including developing indicators
that will enable us to show our progress in
addressing these issues. We will continue to build
on these steps to increase the transparency of our
operations. In this way we expect to give our
stakeholders the same confidence in the value 
of our business that we feel ourselves.
Corporate responsibility is an integral part of 
our business – it is inherent in the mission of 
the company. GSK makes a significant positive
contribution to society around the world, through
the medicines, vaccines and healthcare products
that we research, develop, manufacture and sell. 
01
Our products must improve people’s lives to ensure
a profitable and sustainable future for our business.
We also understand that it is not just how much
profit we make that matters. Stakeholders, including
employees, want to know how we make this profit,
and to be reassured of the sound ethical basis for
our business.
We could not run our business effectively without
talking with, and listening to, the many groups our
business impacts. Discussion with stakeholders is a
part of our everyday work. This is very much a two-
way relationship because the views and expectations
of stakeholders directly affect us. 
We consult widely, both formally and in less formal
ways. The diversity of our stakeholders, for example
patients, customers, healthcare professionals,
governments, non-governmental organisations and
shareholders, inevitably gives rise to very different and
sometimes conflicting demands for us to consider.
We will continue our constructive engagement to
guide us in running a successful business that
contributes to meeting the needs of society.
Sir Christopher Hogg
Chairman
JP Garnier
Chief Executive Officer
During 2002, we... 
• invested a total of £239 million in global community
activities, product donations and charitable
contributions – more than any other UK company; 
• donated 66 million albendazole tablets, worth 
£8.7 million, to 31 countries to support the prevention
of lymphatic filariasis;
• increased shipments of our Combivir HIV/AIDS
treatment at preferential prices to the developing
world to nearly 6 million tablets, up from 2.2 million
in 2001; 
• worked with other companies to establish new
industry Principles on the Conduct of Clinical Trials
and Communication of Clinical Trial Results; and 
• surveyed 10,000 of our managers on their views 
of GSK’s Spirit and culture.
GlaxoSmithKline researches,
develops, manufactures and 
markets medicines and consumer 
health products around the world.
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R&D – DISEASES OF THE
DEVELOPING WORLD
Continuing our commitment 
to find preventions and
treatments, particularly for
HIV/AIDS, malaria and TB
(page 7)
MEDICINES FOR THE
DEVELOPING WORLD
Facilitating access to
medicines and improving
health and education 
through partnerships
(page 8)
COMMUNITY
INVESTMENT
Improving the quality of
life of under-served people
in the developed and
developing world
(page 13)
ETHICAL ISSUES 
IN R&D
Considering the questions
that arise from the research
and development of new
medicines and vaccines
(page 17)
Key impact areas
The scope of our business...
over 100,000 employees
operating in 150 countries,
with more than 20 research
and development centres in
8 countries and production
facilities in 38 countries.
commercialise and support effective marketing of
prescription medicines, vaccines and delivery systems
for the treatment and prevention of human disease.
We employ over 15,000 staff in R&D and have more
than 20 R&D sites worldwide.
Our portfolio of products ranges from tablets and
toothpaste to inhalers and capsules. We make over
36,000 different pack sizes and presentations. 
We have a network of 95 manufacturing sites in 
38 countries and employ more than 33,000 in
manufacturing and related support functions. 
Each year we produce over four billion packs, 
which are delivered for sale in over 150 countries.
The pharmaceutical industry is highly regulated, with
every stage from discovery to sales and marketing
closely controlled. Our stakeholders are many and
their expectations can be very different.
Thus, size and complexity make this a challenging
business. This raises many questions about what we 
do, and how and why we do it. Our main impacts on
society, and how we manage these, are described in
this report.
20 24 28
SALES
GlaxoSmithKline
The scope of our business
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DEVELOPING OUR
EMPLOYEES
Attracting, rewarding and
motivating people in a safe
and healthy workplace
(page 21)
SUPPORTING
HUMAN RIGHTS
Respecting the rights 
and interests of all those
affected by and involved 
in our business
(page 22)
CARING FOR
THE ENVIRONMENT
Using resources efficiently
and minimising negative
environmental impacts
(page 25)
BUSINESS
ETHICS
Ensuring our employees
understand and implement 
our Code of Conduct and
policies for ensuring ethical
business practices
(page 29)
GlaxoSmithKline operates in the pharmaceutical and
consumer healthcare sectors, making prescription
medicines, vaccines, over-the-counter medicines, 
oral care and nutritional healthcare products. 
Our business is founded primarily on research and
development to discover, develop, register,
Information on financial performance is available in
the Annual Report and Accounts.
USA PHARMACEUTICALS 46%
EUROPE PHARMACEUTICALS 22%
INTERNATIONAL PHARMACEUTICALS 17%
CONSUMER HEALTHCARE 15%
SALES £21,212m
TRADING PROFIT £6,694m
(Business Performance)
R&D SPEND £2,900m
FINANCIAL PROFILE 2002
The main activity of our company is to
develop medicines, including vaccines,
that make a valuable contribution to
society. These medicines save lives,
relieve suffering, and treat and often
prevent disease. They improve the quality
of life of patients and their carers. They
also enable people to carry on with 
their lives and often reduce the cost 
of managing an illness.
Our contribution to society
In developed countries, because of the availability 
of effective antibiotics and vaccines, we no longer
expect our children to be at risk from infectious
diseases. The challenge is to extend these advances
to developing countries.
The number of diseases where research has
produced major advances continues to grow.
However, there is still much to do. The challenge 
for our company is to continue to meet society’s
expectations by developing innovative medicines
that enable people to live longer and healthier lives.
ACCESS TO MEDICINES
We also want to play a part in improving the
healthcare of people who currently have limited
access to our medicines. Our programmes in
developing countries are set out on page 7.
In the US, we are helping to improve access 
to medicines for low-income senior citizens and 
the disabled who lack prescription drug coverage
through public or private insurance programmes. 
In late 2001, GSK launched the Orange CardSM,
which offers savings on the company’s prescription
medicines. This was the first programme of its 
kind in the US, with participants required simply 
to present the card to their pharmacists to receive
the savings. In addition, last year GSK’s Patient
Assistance Program provided medicines worth 
over £112 million to more than 400,000 low
income patients in the US who do not have 
medical insurance.
Following the positive response to the Orange Card3
from patients, doctors, and companies, GSK and six
other pharmaceutical companies launched a joint
scheme in 2002. The Together Rx™ Card 4 provides
eligible senior citizens and the disabled in the US
with a single, easy-to-use card to receive savings 
on the prescription medicines of the seven
companies involved.
These programmes are having a real impact on the
lives of disadvantaged people across the US.
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The positive effect our medicines have 
on people’s lives is one of the factors that
motivates our employees. The nature of what
we do gives them the opportunity to make a
difference to the health of millions of people
around the world.
CHANGING EXPECTATIONS
With advances in medicine, society has changed 
its expectations of healthcare. Diseases that once
had a devastating impact are now controlled
through improved healthcare management and 
with better medicines and vaccines. This has led
many people in the developed world to take good
health for granted.
For example, a generation ago polio was one of the
world’s most feared infectious diseases. Thanks to
the worldwide vaccination initiative co-ordinated by
the World Health Organization2 and to the major
contribution of our vaccines business, the global
elimination of polio is in sight. 
‘‘GSK is opening up the door for
significant savings to an estimated 10
million Americans. That will make a
tremendous difference in the lives 
of so many people.’’ 
Tommy Thompson US Secretary of Health and Human 
Services on launch of the Orange Card
Case study
DR VINCENT MCGOVERN, A GENERAL
PRACTITIONER IN BELFAST, UK, GIVES HIS
PERSPECTIVE ON ASTHMA MANAGEMENT 
AS BOTH A PATIENT AND A DOCTOR.
A Patient’s Perspective – “The management 
of asthma has changed dramatically over the last 
30 years. I was the child who wanted to play football,
but had to play in goal, who had rounded shoulders
and a blue inhaler in every pocket. I remember
sleepless nights with emergency visits from the
doctor. When inhaled steroids became available they
took away the sleepless nights. The development 
of new treatments has made a huge impact on my 
life. I still have asthma, but it’s well controlled by
preventative treatments. I certainly don’t notice 
I have it, and nobody else does either.”
Asthma-related deaths and hospital admissions have
declined, but the incidence of asthma is growing.
Asthma remains a major health issue worldwide. 
We focus on what matters to patients, concentrating
on their quality of life.
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1970s Ventolin (bronchodilator)
Relieves breathlessness for
3-6 hours per dose
1970s Becotide/Beclovent
(corticosteroid) Reduces the
inflammation in the lungs that 
leads to asthma symptoms
1990s Serevent (bronchodilator)
Relieves breathlessness for up to 
12 hours per dose
1990s Flixotide/Flovent
(corticosteroid) More effectively
reduces the inflammation in the
lungs that leads to asthma
symptoms
Today Seretide/Advair
(bronchodilator/corticosteroid)
The first asthma product that
relieves breathlessness for up to
12 hours per dose and reduces
the inflammation that leads to
asthma symptoms, in one easy
to use device
f
f
f
f
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DEVELOPMENT OF OUR 
ASTHMA TREATMENTS
A Doctor’s Perspective – “As a GP who is also an
asthmatic, I find asthma a really satisfying condition
to treat. It is common, with 5.1 million sufferers in
the UK. In my practice, 80 per cent of the
asthmatics will have mild-to-moderate disease. I aim
to achieve total control of their symptoms using
current treatments, giving them a good quality of
life. And the standard of patient care is getting
higher, either through specialised units or one-to-
one consultations with nurses or doctors. Asthma is
an area where national treatment guidelines have
been adopted and have had a major impact on
disease management.”
Over the last 30 years our R&D organisation has
produced improved medicines to treat asthma and
better ways for them to be taken. These advances
have been vital in enabling healthcare professionals
to provide ever-improving patient care. However,
asthma still causes suffering and even death, so we
will continue our research with the aim of further
improving the lives of the growing number of 
people affected by this disease.
In developing countries, millions of people lack access
to the most basic healthcare services. Life-threatening
diseases such as tuberculosis, malaria and HIV/AIDS
are contributing to a healthcare crisis. 
06
Medicines for the
developing world 
The global community must provide political will,
a significant mobilisation of additional resources,
and a spirit of partnership if we are to see an
improvement in healthcare and quality of life
across the developing world.
GlaxoSmithKline is making a vital contribution
to healthcare in developing countries through
action in three areas: investing in research 
and development (R&D) that targets diseases
particularly affecting the developing world;
preferential pricing of our antiretrovirals, 
anti-malarials and vaccines; and community
investment activities and partnerships that
foster effective healthcare5. We made
significant advances in each of these key 
areas during 2002.
R&D FOR DISEASES OF THE DEVELOPING WORLD
Research into diseases of the developing world
(DDW) is particularly important to address unmet
needs, and to minimise the intrinsic threat in all
infectious diseases of resistance developing to
existing treatments. 
A dedicated DDW group has been created within
GSK’s R&D organisation to ensure a focus on this
area. Projects are prioritised primarily on their 
socio-economic and public health benefits rather
than their commercial returns. Our DDW research 
is now focused in dedicated facilities at Tres Cantos
in Spain (see page 11). 
We believe GSK has the industry’s most extensive
portfolio of DDW R&D projects and marketed
products, and that we are the only company
undertaking R&D into the prevention and treatment
of all three of the World Health Organization’s
priority diseases in the developing world – HIV/AIDS,
tuberculosis and malaria. GSK focuses on these 
three diseases. We are also an industry leader in
collaborating with external partners that want 
to use our specialist infrastructure or expertise. 
R&D into diseases that primarily affect the developing
world, such as malaria, differs in important respects
from efforts aimed at diseases for which a developed
world market also exists, such as HIV/AIDS. The lack
of a commercially viable market for DDW treatments
means that public/private partnerships are essential.
Major companies such as GSK can provide
technological, development, manufacturing and
distribution expertise, while public sector partners 
can help fund development costs and ensure that
new medicines and vaccines get to the people who
need them. The partnership approach encourages
R&D and accelerates the product’s uptake in the
developing world. 
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HIV Ziagen/Epivir 
combination
Retrovir
Epivir
Combivir
Ziagen
Trizivir
Agenerase
protease inhibitor*
S. pneumoniae
paediatric
Havrix (hepatitis A)
Engerix B (hepatitis B)
Twinrix (hep A & B)
Infanrix (diptheria, tetanus, 
acellular pertussis)
Tritanrix (diptheria, tetanus,
wholecell pertussis)
Polio Sabin (polio)
Priorix (measles, mumps
and rubella)
Typherix (typhoid)
Hiberix (haemophilus 
influenzae type b)
Vaccines
tafenoquine Malarone
Halfan
Lapdap*
Malaria
sitamaquine
oxibendazole
TB
PHASE III MARKETEDPHASE I
NNRTI
protease inhibitor
integrase inhibitor
HIV
Dengue fever
Hepatitis E
Rotavirus
Meningitis B
Malaria
N. meningitidis
CDA
PHASE II
PRE-CLINICAL
 ACTIVITY
Ziagen/Epivir
combination
S. pneumoniae
paediatric
tafenoquine
PHASE III
✔
✔
✔
sitamaquine
oxibendazole
ZentelOther sit maquine
oxibendazole
✔
* being registered and not yet marketed.
DDW DEVELOPMENT PIPELINE at end of 2002
We will maintain broadly the current level of human
and financial resources dedicated to DDW as a
proportion of our total R&D investment. We will
work assiduously, with partners when appropriate, 
to ensure that any promising DDW drug is made
available to patients as rapidly as possible. The R&D
process is lengthy and risky. However, our long-
term commitment is now bearing fruit and we are
hopeful that we will be able to launch several new
products relevant to DDW over the next five years. 
We have seen some notable progress in 2002. 
In HIV/AIDS the first human clinical trials of our 
HIV candidate vaccine commenced in February, in
collaboration with the US Government’s National
Institutes of Health HIV Vaccine Trials Network6. 
In conjunction with other partners, GSK continues to
support 29 HIV clinical trials in developing countries,
including 20 in Africa. The purpose of these trials is to
assess the use of antiretroviral therapy for treatment,
and prevention of mother-to-child HIV transmission in
resource-poor settings. Over 10,000 patients form or
will form part of our HIV collaborative studies. Three
thousand of these patients will be included in the
DART Trial (Developing Antiretroviral Therapy) in
Uganda and Zimbabwe, co-ordinated by the UK
Medical Research Council.
There has been progress in malaria too. In October
2002, we submitted a regulatory application to the
UK Medicines Control Agency (MCA) for Lapdap
(chlorproguanil/dapsone) for the treatment of the
most life threatening type of the malaria. MCA
approval will be an important step in making Lapdap
available across Africa, where there is great need for
new malaria treatments. 
Lapdap results from a successful partnership
between GSK, the World Health Organization, 
the University of Liverpool, the London School 
of Hygiene & Tropical Medicine, and the UK
Department for International Development (DFID)7.
This is the first such product development to be
directly sponsored by DFID. 
PREFERENTIAL PRICING
GSK recognises that it has a responsibility to make
its products as affordable as possible in the poorest
countries. We have offered our vaccines to public
health programmes at significant discounts for over
20 years. We set a single, sustainable, not-for-profit
preferential price for each of our antiretrovirals
(ARVs) and anti-malarials to a wide range of
customers in the Least Developed Countries and
sub-Saharan Africa – a total of 63 countries. These
customers include the public sector, not-for-profit
NGOs, aid agencies, UN agencies, and international
purchase funds such as the Global Fund to fight
AIDS, TB and Malaria. We also extend our offer 
of not-for-profit prices on ARVs to employers in 
sub-Saharan Africa who provide care and treatment
through workplace clinics and similar arrangements.
GSK is committed to contributing to health
improvements in a sustainable manner, so we set 
our preferential prices for ARVs and anti-malarials 
at levels that cover direct costs but on which we do
not make a profit. In this way we can offer these
prices for as long as patients need treatment8.
Our long-term commitment is now
bearing fruit and we are hopeful that
we will be able to launch several new
products relevant to DDW over the
next five years.
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NUMBER OF SUPPLY ARRANGEMENTS FOR ARVs
AND TYPE OF CUSTOMER
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We have pledged to pass on cost efficiencies as
shipments to the developing world increase. For
instance, in September 2002, we further reduced
the not-for-profit preferential prices of our HIV/AIDS
medicines by up to 33 per cent and our anti-malarial
medicines by up to 38 per cent9. 
By the end of 2002, we had secured 124
arrangements to supply preferentially-priced ARVs 
to 50 countries. This includes 49 arrangements made
during 2002. These arrangements are with a wide
range of stakeholders, including governments,
NGOs, public hospitals and employers such as
Heineken and Anglo American, with whom we
commenced partnerships in 2002. 
As a result, we increased shipments of Combivir
to the developing world from 2.2 million tablets 
in 2001 to nearly 6 million tablets in 2002 – the
equivalent of about 3 million daily doses. These
figures exclude the product destined for patients 
in Africa which was diverted back to Europe. The
victims of this trade are HIV/AIDS patients in Africa
and the only beneficiaries are the illegal importers.
GSK has introduced special ‘Access’ packs to make
this illegal trade more difficult. We look to regulatory
authorities and our customers to also take measures
to prevent diversion.
GSK’s ability to provide preferential prices to the
developing world requires a sustainable framework.
Our commitment to preferential pricing must be
combined with commitments from others to prevent
product diversion and to avoid referencing developed
country prices against preferentially-priced medicines.
Clearly diversion threatens this framework.
Additionally, in 2002, we started small-scale
shipments of a wider range of preferentially-priced
products to the five pilot projects we have in
partnership with NGOs in Tanzania, Uganda, Nigeria,
Zambia and Malawi. These projects are designed to
assess the impact of preferential pricing for a
broader range of products.
COMMUNITY INVESTMENT PROGRAMMES
We have a wide range of partnerships in the
developing world. Our focus is on health and
education programmes for under-served communities
around the world10. In 2002, GSK invested over 
£12 million in its public health programmes.
Our partners range from the World Health
Organization and the World Bank to local schools
and community-based organisations. Where possible,
we ensure that our programmes are sustainable and
can be repeated in communities with similar needs.
Our programmes comprise major initiatives in public
health, support for education, product donations, 
and support for employee involvement activities. 
Our public health programmes, for example, include:
The Global Alliance to Eliminate Lymphatic
Filariasis – GSK is a key partner in the global effort
to eliminate lymphatic filariasis (LF), also known as
elephantiasis. This is a disabling and disfiguring
disease that currently affects 120 million people, 
and threatens a further one billion, in some of 
the poorest nations of the world11.
CUMULATIVE SHIPMENTS OF COMBIVIR TABLETS 
(EXCLUDING DIVERTED PRODUCT)
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GSK is a founding member of the partnership that
includes the World Health Organization, the Ministries
of Health of the LF-endemic countries, and 40
organisations in the public, private and academic
sectors. GSK donates its antiparasitic drug albendazole,
one of three drugs used to stop transmission of the
disease. Over the anticipated 20-year life of the
programme, this commitment will build to an
estimated six billion tablets as more countries join. 
In addition, we provide significant financial resources
and staff expertise to support coalition-building,
advocacy, research, community mobilisation, and
educational initiatives. 
In 2002, the fourth year of the programme, 66 million
tablets (worth £8.7 million) were donated to 31
countries, bringing the total number of albendazole
tablets donated to date to 145 million. Grants totalling
£750,000 were also made. A huge mobilisation of
effort is required for the fight against LF. This is
exemplified by the more than 45,000 health workers
and volunteers in Sri Lanka who worked together to
deliver preventative medicines to 9 million people in 
a single day in July 2002.
Positive Action programme – In 2002, GSK’s
international programme of HIV education, care 
and community support, backed 25 international
programmes in 32 countries12. Activities funded by
Positive Action support the two-year ‘Live and Let
Live’ World AIDS Campaign launched by UNAIDS on
World AIDS Day 2002. For example, Positive Action-
funded studies by the International Center for
Research on Women, conducted in Ethiopia,
Tanzania and Zambia, have confirmed that societal
discrimination based on HIV fuels the spread of
AIDS. Positive Action also announced funding for
new community initiatives in Kenya and Mexico13.
During the 14th International AIDS Conference, 
held in Barcelona in July 2002, Positive Action
contributed over £90,000 to support attendance 
and participation of community representatives 
from under-resourced regions. 
The GSK France Foundation – supports
programmes that prevent the risk of vertical
transmission of HIV; provide medical care,
monitoring and treatment; and improve access and
quality of care for people living with HIV. In 2002,
the Foundation supported 13 programmes involving
42,000 people as part of a four year £1.3 million
commitment in eight African countries14.
African Malaria Partnership (AMP) – in November
three organisations were selected to share grants
totalling £1.0 million over three years under the
AMP. Through this programme, GSK is funding
behavioural development initiatives to combat a
disease that kills over one million people every year.
In total nearly two million people will be reached by
the programmes in the seven countries involved15. 
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Our partners range from the World
Health Organization and the World Bank
to local schools and community-based
organisations.
1999 2000 2001 2002
M
ill
io
n
s
80
60
40
20
0
Years
“GlaxoSmithKline has much to be proud of in improving
healthcare in the developing world through its drug distribution, 
research and development, and community activities. The world’s 
attention is focused on private companies and governments as
we work together.”
Constance A. Carrino Director, Office of HIV/AIDS, USAID
Estimated patients treated (m) Tablets donated (m)
Key
LF ELIMINATION PROGRAMME
145 million albendazole tablets 
donated to date
Case study
GSK’s Tres Cantos site houses major elements 
of our R&D high-throughput screening activities
and GSK’s commercial operations in Spain.
However, we have now also concentrated our
DDW drug research in TB and malaria – efforts
with a long history in GSK – into dedicated
facilities on the site, with a full-time research
staff committed solely to DDW.
As well as the centre’s TB and malaria focus, ideas 
and drug candidates for treating other neglected 
diseases of the developing world are pursued
opportunistically, and the development of existing
GSK drug candidates for such diseases will continue.
The Tres Cantos DDW scientific staff provide the
wide range of skills – including chemistry, biology
and toxicology – needed to better understand the
disease targets and identify novel drug candidates
for further development. Such a concentration of
resources and skills maximises our ability to discover
new medicines for DDW.
The Tres Cantos group is fully integrated with the
rest of GSK’s R&D in order to ensure that we can
bring all the relevant skills, technologies and
resources to bear to achieve success in developing
such discoveries. In this regard, GSK’s advantages 
of scale and our networks with key external
partners are important. 
In particular, access to GSK’s world-wide clinical
development organisation is vital for the effective
conduct of clinical trials. However, the DDW group
at Tres Cantos, and its associated DDW drug
development team in London, can also call on 
GSK’s expertise and staff in many other areas, 
such as screening, pre-clinical development and 
regulatory affairs.
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GSK’s research into Diseases of the
Developing World (DDW) is centred on
dedicated R&D facilities in Tres Cantos,
Spain. This is in addition to our HIV/AIDS
and vaccines R&D programmes. 
The total value of our community investment
activities in 2002 was £239 million.
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Project HOPE airlift of
GSK antibiotics to
Tajikistan. Our product
donations for humanitarian
relief reached 73 countries
in 2002.
We work with partner organisations around 
the world to ensure that the right blend of
expertise is applied to each of our programmes,
and we select partners who have the best
experience and skills for each initiative.
Programmes are selected on the basis of
community need, not for their potential impact
on GSK’s commercial business or to increase
sales of our products. We fund programmes that
are measurable, sustainable and replicable and
we work closely with our partners to ensure
their success16.
WORLDWIDE COMMUNITY CONTRIBUTION
GSK’s community investment and charitable
contributions in 2002 totalled £239 million, of which
£112 million was related to the company’s Patient
Assistance Program for financially disadvantaged
patients in the US. Our corporate regional public
health and humanitarian relief programmes aim to
serve communities with the greatest needs. To meet
local needs GSK operating companies also support
numerous local community programmes.
GSK product donations for humanitarian relief are
made through charitable partner organisations that
have experience in delivering humanitarian relief.
These charities decide where and when our product
donations are most needed, and work with
governments of recipient countries to ensure that
they arrive safely and are distributed appropriately.
For example, a donation of almost half a million
treatments of our antibiotic Augmentin was part 
of an airlift of vital medicines into Tajikistan in
October 2002 organised by Project HOPE17. 
Already struggling to overcome the effects of 
civil war, Tajikistan has been further challenged 
Community investment
The focus for GlaxoSmithKline’s community
investments is on improving health and education. 
Our programmes extend to both the developed 
and developing world, and most of our efforts are
targeted at improving the quality of life of people 
in under-served communities.
by a decade of steady immigration of refugees from
Afghanistan. As a member of the Partnership for
Quality Medical Donations, GSK has fully endorsed
and agreed to follow the WHO Guidelines for 
Drug Donations18.
Our public health programmes are directed to 
areas where specific diseases are prevalent. This
means that our HIV/AIDS community programme,
Positive Action, has global reach; our effort to
eliminate the parasitic disease, lymphatic filariasis, 
is focused on endemic countries in the developing
world; and our African Malaria Partnership is
directed to the continent that bears the greatest
burden of the disease (see page 10).
In the developed world too, our community
programmes support communities in need. 
Our SHARE programme in the US and Canada 
targets health in elderly, racial and ethnic minority
communities. We are providing monetary awards 
for innovation and sharing best practice on reducing
health inequality among these vulnerable groups19.
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We fund programmes that
are measurable, sustainable
and replicable and we work
closely with our partners to
ensure their success .
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In 2002, the International Business Leaders Forum
Award for International Corporate Citizenship was
made to GSK for our PHASE programme which
provides hygiene education for school children.
“As a charity, Plan UK has been very impressed by GSK’s approach 
to partnership. They have been willing to consult with local
communities, to develop materials which are easy to use, relevant
to local culture and save children’s lives.”
Marie Staunton Executive Director of Plan International 
“The PHASE programme is making a real difference to the health 
and well-being of local communities and is an excellent example
of the positive role that business can have in society.”
Robert Davies Chief Executive of the International Business Leaders Forum
In the UK, as part of a broad commitment to science
education, we have committed up to £1 million over
four years to fund INSPIRE (INnovative Scheme for
Post-docs In Research and Education), a programme
to boost science education in schools20. This
supports selected schools applying to become
Science Colleges under the UK government’s
Specialist Schools Programme. 
GSK provides support in many different ways, 
for example, through donating money, products, 
and other in-kind donations such as office furniture,
computers and surplus laboratory equipment. 
Our product donations are valued at wholesale
acquisition cost which relates to the price GSK
charges wholesalers and warehousing chains, 
not the retail price.
The company follows the London Benchmarking
Group21 model of recording our community
investments. This recognised model provides 
a standard basis for companies to manage and 
report their commitments to the community.
METHOD OF GIVING
(including US Patient
Assistance Program)
Cash
42%
Public Health Programmes (including LF) 10%
Product Donations 12%
Corporate and Regional Programmes 11%
Local Programmes 67%
TYPE OF PROGRAMME
(excluding US Patient Assistance Program)
In Kind
1%
Product
57%
Case study
In 1998 GSK launched an initiative called PHASE
– Personal Hygiene And Sanitation Education –
to provide hygiene education for school
children, with the aim of reducing diarrhoea-
related disease and deaths associated with 
poor hygiene.
PHASE started in partnership with AMREF (African
Medical and Research Foundation) and operates 
in Kenya, Nicaragua and Peru, where GSK has
committed £1.2 million for its roll-out. In Latin
America, GSK works with the child-focused
development charity Plan International. In Kenya,
83,000 children in 247 schools are benefiting from
this basic education, while in Nicaragua it will 
reach over 27,000 primary school children and
20,000 in Peru.
PHASE empowers children and their families 
to take responsibility for their own health and
sanitation. Communities around the participating
schools have also benefited, with most homes now
having containers for handwashing, pit latrines 
and refuse pits. 
Evaluation of the Kenyan programme has shown
that, as a result of PHASE, children have a better
understanding of the causes of diarrhoea and 
worm infestations, and know about ways to 
prevent infection. Teachers have seen improvements
in school attendance and report that children are 
now much cleaner and take better care of their
personal hygiene. Data from one class show that
the percentage of children who knew that washing
hands after going to the toilet could prevent worms
increased from 20 per cent before PHASE to 
45 per cent afterwards. 
The success of the programme has been such that
the Kenyan government has incorporated PHASE
into the national curriculum, increasing the
likelihood of these benefits being available to 
other parts of Kenya. 
A wide range of seriously debilitating and life-
threatening diseases thrive in the poor living
conditions found in many countries of the
developing world. In Africa alone, over 3.5 million
children die each year from diarrhoeal disease.
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We understand the need to balance the benefits
that patients gain from new medicines with any
risks or ethical considerations relating 
to new technologies.
16
If we are unable to take advantage of
advances, patients will not have the best
treatments. We understand concerns about
technological advances in the R&D process, 
and welcome informed debate.
The R&D process is highly regulated, wherever 
we operate. As scientific advances raise new issues, 
we work closely with the regulators, policy makers
and stakeholders to develop any new or refined
standards. We have our own internal standards and
systems to ensure that we comply with or exceed 
all guidelines, regulations and legal requirements.
THE ESSENTIAL ROLE OF ANIMAL RESEARCH
Basic research using animals is vital to furthering 
our understanding of human disease. Animal
studies also provide an essential bridge between
characterising potential new medicines and vaccines
in the laboratory and learning about their effects 
in people. By law, we must assess drug safety 
in animals before starting clinical trials. We are
committed to the three Rs – to reduce, refine and
replace animal studies – and set stringent standards
internally and for our external contractors. We
ensure that all GSK staff conducting animal studies
are thoroughly trained. 
We reduce the number of animals used in research
wherever we can without compromising the safety
of volunteers and patients in clinical trials, and we
seek as much information as possible from each
animal study. The number of animals used in our
laboratories has therefore remained essentially
constant over the last eight years in spite of a
significant increase in our R&D activity (see chart,
page 18). We use animals more humanely by using,
for example, non-invasive imaging (see page 19).
Research and
development
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We encourage staff to devise alternative approaches
to animal research through internal Animal Welfare
Awards. GSK sponsors the largest European award 
in this field – the GSK Laboratory Animal Welfare
Prize22. Inspections by national regulatory
authorities acknowledge the high standards of care
and compliance in our facilities. To ensure that we
meet best practice, our US and UK animal facilities
are accredited by the Association for Assessment 
& Accreditation of Laboratory Animal Care23, and 
we are working to extend this to our other facilities. 
We believe that the best way to address public
interest in animal research is to foster greater
knowledge and understanding of the facts. 
We also believe that this is the most effective way
to help combat the climate of fear and intimidation
being promoted by animal extremist groups. We
therefore provide information to support rational
public debate, actively participate in such discussions
ourselves and host tours of our animal facilities
where possible. We also welcome government
actions to protect our staff, laboratory animals 
and research collaborators from extremist actions.
We visit schools to discuss relevant ethical issues, 
for example, involving over 2000 UK pupils in 
such discussions in the 2001-2 school year. 
Information on GSK’s use of animals in research is available 
on our website 24.
GlaxoSmithKline aims to produce safe and effective
medicines and vaccines that benefit patients by
addressing their unmet medical needs. To do this,
we need to use the most recent advances in science
and technology to understand diseases and to
identify and test drugs. 
THE “THREE RS”
IN ANIMAL RESEARCH
Reduce the number of animals
used in medicines R&D to the
minimum possible to obtain
meaningful, validated results.
Refine animal experimental
procedures to avoid or minimise
pain or discomfort, and to
maximise the information
obtained from each study 
and each animal.
Replace the need for animal
studies by developing and
validating alternative approaches
wherever feasible.
REDUCE
REFINE
REPLACE
We are obliged by law 
to assess drug safety in
animals before starting
clinical trials.
TESTING NEW MEDICINES IN CLINICAL TRIALS
GSK’s aim, to develop medicines and vaccines that
benefit patients, is reflected in the priority we give 
to protecting the interests of healthy volunteers 
and patients who take part in our clinical trials. 
The regulatory authorities rigorously scrutinise the
initiation and conduct of clinical trials and related
activities. The need to respect the rights, dignity,
safety and well-being of clinical trial participants is
enshrined in declarations and guidelines produced 
by the World Medical Association, World Health
Organization, Council of the International
Organisations of Medical Sciences, Council 
of Europe, the International Conference on
Harmonisation (ICH) and government bodies. 
GSK fully complies with the relevant regulations and
national requirements, and with guidelines such as
ICH Good Clinical Practice. When regulations and
guidelines are periodically reviewed and revised 
to ensure that they fully address the interests of
patients, GSK actively contributes to the discussions
on the basis of our extensive global experience.
In our last review, we summarised our rigorous
procedures to ensure patient safety and the privacy
of their medical information. We have recently
strengthened procedures to avoid information being
sent to GSK by external investigators that would
enable us to identify trial participants. However, 
we know that the conduct of clinical trials raises
ethical issues and we therefore worked with other
companies in 2002 to establish the new PhRMA
Principles on the Conduct of Clinical Trials and
Communication of Clinical Trial Results 25.
The Principles reflect the importance of independent
Institutional Review Boards or Ethical Review
Committees in protecting patients and volunteers
involved in clinical trials. GSK fully supports these
guidelines, which reiterate the need to obtain
genuinely informed consent before any clinical
procedure is undertaken, an obligation that GSK
extends to include acquiring and using human
biological samples such as tissues and DNA. The
Principles also summarise the safeguards the 
industry, including GSK, adopts to ensure that the
reimbursement of patients’ and external clinical
investigators’ expenses is not an inappropriate
inducement to participate in clinical trials, or to bias
the results that are reported. Regulatory authorities’
requirements for financial disclosure further protect
the public interest in this area.
The Principles articulate the industry’s, and GSK’s,
practice of seeking to publish the meaningful results
of controlled clinical trials, regardless of the outcome,
in a timely manner. This includes giving clinical trialists
the appropriate level of access to the raw data and
their interpretation.
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Rapid technological advances have provided 
us with the tools to make major progress in 
the fight against disease.
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CHANGE IN R&D ACTIVITY COMPARED WITH CHANGE IN
NUMBER OF ANIMALS USED BY GSK
Animals used R&D activityFigures normalised to 1994 levels Key
Case study
REFINING RESEARCH USING ANIMALS
When studying a disease or the effect of a drug
over a period of time, animals would previously
have had to be humanely killed and the organs
removed for microscopic examination at each
time-point. MRI enables the same animal to be
repeatedly assessed at each time-point so the
number of animals used is reduced. 
Moreover, we can get more detailed information
about the progress of a disease by more frequent
scanning than would be possible if every time-point
needed a separate group of animals and resource-
intensive technologies such as microscopic
examination. Importantly, each animal can often 
be used as its own control so the statistical power 
of these studies is enhanced even when using far
fewer animals.
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Serial MRI allows respiratory biologists to study lung
inflammation in rats that mimics some aspects of
human asthma. The same animals are scanned,
minimising discomfort, for several weeks. This allows
chronic inflammatory and other responses to be
studied, and the beneficial effects of standard and
new drugs to be measured. The MRI approach
typically requires 24 animals for a study that would
require more than 500 if undertaken using
conventional microscopy approaches. 
Similar approaches are being taken in our other
research areas, such as neurology, psychiatry and
cardiovascular diseases, as well as in preclinical
safety assessment. The cumulative beneficial impact
on 
the number of animals used and on data quality is
therefore very significant.
Non-invasive imaging techniques such as
magnetic resonance imaging (MRI) can provide
new and more relevant scientific information in
ways not previously possible.
GSK employs over 100,000 people and
operates in more than 150 countries.
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We are committed to providing the opportunity
for our employees to do meaningful and
challenging work in pursuit of our goal to
improve the quality of human life by enabling
people to do more, feel better and live longer.
Last year we reported on the principles that underpin
our approach to people management, and a range of
programmes which were designed to deliver our global
human resources strategy. We are now pleased to
report the progress we have made and set out, where
we are able, how we intend in future to measure our
performance on issues such as diversity.
THE GSK CULTURE
At GSK, great emphasis is placed not only on what
we must achieve as a company, but also on how 
we deliver our achievements. Our culture is summed
up in the GSK Spirit which defines the qualities 
we expect all our employees to embrace:
• performance with integrity
• entrepreneurial spirit
• focus on innovation
• a sense of urgency
• passion for achievement
Developing the GSK culture is critical to enabling
people to reach their potential and do their best
work. We therefore carried out a survey in 2002 of
10,000 managers to assess how well the Spirit and
culture is being adopted. We sought views on the
experience of working for GSK, including both what
managers considered was being done well and what
areas needed further work.
The survey results were generally very positive,
showing that managers take great pride in being 
part of GSK. For example, there was overwhelming
support for the statements that “people in my
department show commitment to performance with
integrity”, “my department is a focused organisation
with a sense of urgency” and “I would gladly refer 
a good friend or family member to GSK for
employment”. These findings show that managers
believe that the GSK Spirit is reflected in the way 
they and others are working day to day.
The results also raised important areas for further
development. These included concerns about whether
people are able to perform to their full potential, the
extent to which managers are able to act as coaches
to support development, and the degree of staff
involvement in decisions that affect their work. These
issues are all being addressed by GSK’s Corporate
Executive Team. For example, a programme has been
put in place to reduce complexity and bureaucracy in
the company and to streamline processes to help free
up managers to do their best work.
Valuing people
People are the greatest single source 
of competitive advantage for any company.
At GlaxoSmithKline, we believe that attracting,
retaining and motivating the very best people 
is the foundation for our future success. 
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The survey results were
generally very positive,
showing that managers 
take great pride in being 
part of GSK. 
HUMAN RIGHTS 
GSK believes that on human rights issues, we 
can lead by example and thereby influence the
behaviours and practices of others through clear
demonstration of our own values. Our most effective
contribution can be made through pursuing policies
in our own operations that respect the rights and
interests of all those affected by and involved in 
our business. GSK supports and is committed to
upholding the United Nations Universal Declaration
of Human Rights26 and the core labour standards
set out by the International Labour Organization27.
During 2002, we carried out an internal review
which demonstrated that, wherever we operate 
as an employer, we believe we are complying with 
the Universal Declaration of Human Rights and 
the core conventions of the International Labour
Organization, and according to the Guidelines 
for Multinational Enterprises set by the OECD28.
Conducted through the Head of Human Resources
for each country, the review was also used to 
build awareness and understanding of human 
rights issues.
Also during the year, we began to put in place
binding requirements to ensure that our major
contractors and suppliers adopt GSK’s standards 
on human rights and core labour standards. 
DIVERSITY
Diversity is a business imperative for GSK; we 
are committed to the principles of equality of
opportunity and equal treatment. We aim to have 
a workforce and working environment that reflects
the diversity of background, culture, beliefs 
and characteristics of the communities in which 
we operate. 
We are therefore embedding the values of diversity
and equal treatment into our key business processes.
For employees, this means that diversity measures are
included in manager and employee training, external
recruitment and internal appointment processes,
performance assessments and pay reviews,
succession planning and developmental assignments.
For customers and stakeholders, it includes 
the development of measures to reach targeted
customers, outreach programmes for specific 
patient groups and advertising that reflects the 
many communities we serve.
We believe that our diversity strategy will show clear
progress against the baseline figures we report this
year (see below). We will report changes annually. 
With the exception of the US (see ethnicity chart),
we do not have meaningful data on the ethnicity of
our employees because of the different ways ethnic
groups are described in different countries and, 
in some cases, because of legal restrictions on
collecting these data.
We are fundamentally committed to 
the principles of equality of opportunity 
and equal treatment.
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Bands A & B* 583 (81%) 134 (19%)
Bands C 1-3** 2708 (70%) 1159 (30%)
Bands C 4 & 5*** 4409 (65%) 2343 (35%)
Total 7700 (68%) 3636 (32%)
GLOBAL SENIOR MANAGEMENT POPULATION BY 
GENDER 2002
Men Women
* Corporate Executive Team and Vice-Presidents/Senior Vice Presidents
** Director Level
*** Manager Level
ETHNICITY OF US EMPLOYEE POPULATION, 2002
Total US employees 24,000
19%
People of
colour
Case study
Our promotion of diversity within GSK has
had a powerful effect on the way we think
about the needs of our customers. 
23
Ensuring that our medicines benefit the widest
possible number of patients is at the heart of 
our mission to enable people to do more, feel 
better and live longer. In 2001, one of GSK’s 
General Pharma sales and marketing units in 
the US made it a key business objective to
improve access to GSK medicines to patients
from ethnic minority communities.
The unit operates in a part of southern California
with a particularly high population of Vietnamese,
Koreans, Armenians, Central Americans and
Mexicans. 
The sales teams had specific training on cultural
awareness to improve their understanding of their
customers and their particular needs. As a result,
doctors are better able to use GSK products, 
with benefits for individual patients and for 
these communities.
Building on this success, cultural awareness training
was extended to all sales groups across the US
during 2002. This approach is also being used 
in GSK’s US Pharma marketing departments 
to increase multicultural awareness and
understanding relating to each of our brands. 
In addition, through our multi-language patient
education programme, we are supporting US
healthcare professionals in raising awareness of
diseases and disease management among groups
with limited command of English. Disease education
materials on asthma, migraine, rhinitis and
depression are being provided by GSK sales
representatives in a number of languages including
Spanish, Chinese, Vietnamese, Korean and Russian.
GSK has a comprehensive programme to characterise
the physical and chemical properties, environmental
fate and effects, and occupational health effects of
our products and chemical processes.
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Although many of the contractors on our sites do
not work under our direct supervision, their safety is
as important as that of our employees. We apply the
same standards to them, and monitor their health
and safety. For external contractors working for GSK,
the lost time injury and illness rate was similar to the
rate for our own employees.
We improve our EHS performance by having strong
EHS management systems and programmes in place.
Four examples are given below.
EHS information for our products and processes
GSK has a comprehensive programme to
characterise the physical and chemical properties,
environmental fate and effects, and occupational
health effects of our products and chemical
processes. This information helps us to: 
design and operate our production and control
systems to protect our employees and the
communities in which we operate.
inform our employees and the public about 
the hazards of materials to help them understand
how to handle them safely.
We have a comprehensive framework of
environmental, health and safety programmes
that provide the structure for our approach.
This is based on EHS Standards that apply,
without exception, to all of our sites around 
the world.
Environmental sustainability is the basis of our
environmental programmes. After addressing the
potential for adverse impacts from our wastes, 
our approach to achieving sustainability is to focus
on improving the efficiency of our manufacturing
processes to minimise the materials used and 
waste generated, and then to optimise the use 
of renewable raw materials.
Our occupational health and safety programmes
focus on protecting and enhancing the health and
safety of our employees, reflecting the value we
place on people.
IMPROVEMENT TARGETS
Our EHS performance targets are set against
baseline performance in 2001, the first full year 
of GSK’s operations, and are to be achieved by 
the end of 2005. For environmental emissions,
company-wide targets have been set by
consolidating individual site targets.
Our health and safety target is to reduce lost time
injuries and illnesses by 15 per cent each year to
2005, from a baseline rate in 2001 of 0.43 lost 
time injuries and illnesses for each 100,000 hours
worked. Preliminary data for 2002 indicate that we
will meet this target for the year. Final verified results
will be on our website, www.gsk.com.
As a responsible global citizen,
GlaxoSmithKline strives to preserve 
the environment and protect the 
health of people who work for us. 
Environment,
health and safety
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One of GSK’s dry powder devices
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EXAMPLES OF ENVIRONMENTAL 
PERFORMANCE IMPROVEMENTS
Contract manufacturers
GSK uses contract manufacturers in a number 
of countries to supply certain products for local
markets and, in a few cases, for specialist processes
or technologies. They are an integral part of the
product supply chain so we work with them to
prevent adverse events and ensure the reliability 
of product supply. To ensure that these companies
are managing EHS risks and impacts responsibly,
conformance with GSK requirements and legislation
is assessed through a programme of EHS audits
conducted by our EHS Global Audit Team.
The audits cover general management of EHS 
and control of key risks and impacts. Areas for
improvement are highlighted to the contract
manufacturer and progress is monitored. In 2002, 
16 key contract manufacturers/suppliers were assessed.
Ozone depletion and chlorofluorocarbon (CFC)
elimination – Metered dose inhalers (MDIs) are 
the most common way that asthmatics receive 
their medication. However, many MDIs use as
propellants CFCs that are ozone depleting and
global warming gases.
Currently GSK has an extensive plan containing 
over 10,000 milestones to eliminate CFCs from 
our MDIs. Progress is excellent with 68 per cent of
the actions completed. In 2002, for the first time
since the transition began, GSK manufactured over
100 million non-CFC MDIs and launched our first 
non-CFC MDI in the US, CFC-free Ventolin. Coupled
with offering a wide choice of dry powder devices
we are confident in our ability to transition away
from CFCs. We therefore believe that the Montreal
Protocol ‘essential-use’ exemption that allows the
manufacture of CFCs for salbutamol/albuterol 
(the active ingredient in Ventolin) MDIs, and the
marketing of salbutamol/albuterol MDIs containing
CFCs, is no longer necessary.
Contaminated land
We are currently studying or actively cleaning up 
31 sites that are classed as contaminated land. 
We are also remediating a number of our former
manufacturing sites in preparation for their
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decommissioning or sale. GSK has spent over 
£100 million to date and expects to spend about 
£30 million on further remediation at existing sites.
When designing and implementing remediation
projects, we work with government agencies and
local communities to use the best technologies
available to clean up the land to allow return to
other use such as community parklands.
At most of these sites, land has been contaminated
due to past storage and disposal practices, including
poor containment or accidental releases at
commercial disposal sites. The global standards and
systems we now have in place to cover all phases of
waste management are designed to prevent future
incidents that could contaminate land.
ENVIRONMENTAL PERFORMANCE 
Both GSK’s heritage companies realised the benefit 
of setting targets to improve environmental
performance. Improvement projects were started in
the 1980s and will continue into the future. The chart
below illustrates the improvements already achieved in
air emissions (VOC), wastewater discharges (COD) and
hazardous waste disposed in the three years leading
up to the GSK baseline of 2001.
The most recent performance data against EHS
targets are available on our website29.
Figures normalised by sales
VOC (Volatile Organic Compounds emitted to air)
COD (Chemical Oxygen Demand in wastewater)
HWD (Hazardous Waste Disposed)
Key
TARGET
Case study
Innovative approaches delivered an
excellent safety record during the
construction of GSK’s new Horlicks
plant in India.
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GSK has recently completed building a new
factory at Sonepat in the north of India to meet
growing demand in the country for Horlicks,
one of GSK’s most popular nutritional drinks.
The project involved over 17,000 construction
personnel and a total of 13.4 million hours of 
work over 3.5 years. At its peak, there were 1,900
workers on the site at one time. Most workers were
on site for less than 60 days, so ensuring that the
changing workforce was made aware of the safety
and health issues was a significant challenge.
Health and safety were given priority when
construction was planned, and appropriate
programmes were put in place on the site. These
included providing a 24-hour site health facility, 
so that injuries and illnesses could be treated early and
workers did not need to leave the site for treatment.
Induction training for new workers emphasised safety,
inspectors monitored high-risk areas on the site, and
weekly talks on safety topics and special training
programmes for scaffolders were held.
This was a new approach for a major greenfield 
site construction project in India, where historically
projects of this type do not involve a high level 
of attention to health and safety, and where formal
safety training is not common. As a result of these
initiatives, accomplished in partnership with
construction management and subcontract
companies, Sonepat returned one of the best 
lost-time accident figures seen in projects within
GSK and its legacy companies. Benefits of the
health and safety planning were demonstrated
immediately and improved over the course of the
project so that the last 6.6 million hours were
worked without any lost-time injuries or illnesses. 
A lasting benefit of this project is the future
application of lessons learned in creating a 
safety culture.
This project won the 2002 EHS Initiative Award
which is sponsored by the Chief Executive Officer. 
It was selected by a panel of judges representing
academia, government, NGOs and GSK’s Board 
of Directors.
High standards of honesty and integrity are vital 
to the success of our business.“Performance with
integrity” is the principle by which we aim to live
and work at GSK.
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CORPORATE ETHICS AND COMPLIANCE
GSK is committed to operating within the law 
and to the highest ethical standards. The healthcare
industry is highly regulated and the discovery,
development, manufacturing and marketing of
medicines are complex processes. Thus, we aim to
build adherence to high standards into the everyday
management processes of these activities. 
Formal company polices and procedures set out 
the expected standards of conduct, but effective
communication and training on these standards,
followed by regular monitoring and periodic review
of work output, are critical. While lawyers and
compliance officers are closely involved in establishing
and communicating standards, GSK emphasises the
personal responsibility of employees and their line
managers for ensuring that all employees observe
these principles in their everyday work. To support
this we undertake ethics training through computer-
based sessions and interactive discussions.
The Corporate Ethics and Compliance function at
GSK is responsible for supporting the development 
and implementation of practices that facilitate
employees’ compliance with laws and company 
policy. Specialist compliance officers support 
our main operations of Pharmaceuticals, Consumer
Healthcare, R&D and Manufacturing.
An internal control framework integrates ethics 
and compliance with the day-to-day management
of the Group. This framework supports line
management in the identification and mitigation 
of significant risks, among which are potential
compliance failures. 
Business ethics and integrity
GlaxoSmithKline’s Code of Conduct lays out the
principles that the company values and that employees
should apply in their daily work. It is the responsibility 
of each employee to implement the Code to sustain 
the trust and confidence of all GSK’s stakeholders.
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The framework includes a Risk Oversight and
Compliance Council, as well as sector and other
business unit risk management and compliance
boards. The Risk Oversight and Compliance Council
and boards assist in the identification and mitigation
of risks and provide guidance on risk management
initiatives at the corporate and business unit levels.
The Risk Oversight and Compliance Council reports
to the Audit Committee of the GSK Board and the
Chief Executive Officer, and will also report to the
Corporate Executive Team. The reporting line to 
the Audit Committee provides a mechanism for
bypassing the executive management if irregularities
are ever identified. 
GSK RISK MANAGEMENT & COMPLIANCE FRAMEWORK
GSK BOARD
CEO
CET BUSINESS AND FUNCTION HEADS
RISK OVERSIGHT AND COMPLIANCE COUNCIL (ROCC)
BUSINESS UNIT OR FUNCTIONAL RISK MANAGEMENT AND COMPLIANCE BOARDS
BUSINESS AND FUNCTIONAL GROUPS
POTENTIAL RISKS AND RISK-GENERATING ACTIVITIES AND FUNCTIONS
Audit Committee Corporate SocialResponsibility Committee
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GSK POLICIES
The GSK Code of Conduct and all GSK policies are
available on our internal website. In 2002, a guide
to business conduct was published on the internal
website to support employees’ understanding and
implementation of these standards. The guide
summarises policies and explains the company’s
expectations on business ethics and good business
conduct. 
NOTIFICATION SYSTEMS
Confidential Integrity Help Lines to compliance
officers are available for employees to report concerns
they feel are not being dealt with adequately through
the normal management system.
These Help Lines are available to employees in 
the UK and US, reaching about half the total GSK
workforce. Other employees can take advantage of
e-mail access to a compliance officer, or can report
concerns through a confidential post office box
maintained by Corporate Ethics and Compliance.
The Help Lines are primarily used for consultations 
and by employees to ask questions. As a result, 
the number of callers and inquiries received by
compliance officers tends to increase in response 
to training or to changes in or issuance of new
policies. Activity levels reflect greater awareness 
of policies and legal requirements rather than trends 
in unacceptable practices. Response levels indicate
that the existence of the systems and their purpose 
are well understood. 
Confidential toll-free lines to 
compliance officers are available for
employees to report concerns.
Case study
Senior managers in GSK are expected 
to lead by example by working in line 
with the Code of Conduct and other 
GSK policies and in supporting their 
staff to do the same.
To ensure their understanding of this
responsibility, in 2002 GSK introduced a
certification process around the world for
managers at the vice-president level and above.
Certification requires these managers to sign 
a statement confirming their awareness of their
obligations to implement the company Code of
Conduct and policies. This includes confirming that:
They know they are personally obliged to comply
with applicable laws, regulations, and GSK’s
corporate and local policies and procedures.
They accept their responsibility to put in place
appropriate measures to ensure that the people
under their supervision are aware of their own
obligations.
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All people under their supervision have received
copies of, or have access to, the GSK Code of
Conduct and other GSK policies, and understand
their responsibilities.
In 2002, around 700 managers – all those at vice-
president level and above – completed certifications.
We believe this process will further support the
dissemination and awareness of GSK ethical
standards and the Code of Conduct and their
importance to thousands of other GSK employees
who, in the course of their daily activities, must
work in line with the law and GSK policies.
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& REPORTING
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Management of CSR
Our corporate and social responsibility (CSR)
activities, including those covered in this report,
are managed in the most appropriate functions
in the organisation rather than through a central
department. We believe this is the most effective
approach to managing the issues because they
remain an integrated part of the everyday
operation of the business.
To facilitate policy development, implementation 
and communication, a cross-functional team was
established at the beginning of 2002 to ensure 
a comprehensive and co-ordinated approach. The
team is made up of representatives from the key
business areas who ensure that policies are in place
and mechanisms exist for their implementation and
monitoring. The representatives also contribute to
reporting progress through this report and in other
ways, for example through conference presentations 
and on our website.
During the year this cross-functional team developed
indicators that will support reporting on key issues.
In determining the indicators, we aim to strike a
balance between the desires of our stakeholders 
for greater transparency about our operations with
the realities and costs of running the business. 
Contributing to improving people’s lives as a
responsible corporate citizen is an integral and
established part of our business practice.
We also believe that stakeholder discussion on
anything that requires specialist knowledge is best
undertaken by those with such expertise. Hence 
the team representatives discuss issues directly with
those who have expressed an interest or concern,
and central co-ordination means that broader 
issues are brought to the attention of the 
cross-functional team.
GSK has a process in place for identifying, evaluating
and managing significant business risks, and this
includes reputational and corporate responsibility
issues. Our risk management process accords with
the Turnbull guidance and our formal risk assessment
is updated at least once a year. The Risk Oversight
and Compliance Council (see page 29) coordinates
internal control and risk management activities to
ensure effective management of significant risks.
During the year, the CSR committee of Non-
Executive Board members gave advice on how 
we report our activities, and had specific input 
into our approach to community investment,
environment, health and safety and human resources
policies including diversity and human rights issues.
Global Government
Affairs & Public Policy
MEDICINES FOR
THE DEVELOPING
WORLD
R&D – DISEASES
OF THE
DEVELOPING
WORLD
ETHICAL ISSUES 
IN R&D
CARING 
FOR THE
ENVIRONMENT
BUSINESS 
ETHICS
DEVELOPING
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